AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03541551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTT with ologen® Collagen Matrix
Description: ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.
Study NCT03541551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trab Trab
Description: combined trabeculotomy with trabeculectomy
Study NCT01682434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in situ keratomileusis (LASIK)
Description: Wavefront guided treatment in one eye, conventional in the other.
Study NCT04100642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical apply
Study NCT02913417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres® Yttrium 90
Description: Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
Study NCT02913417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: ipilimumab 1mg/kg every 3 weeks x 4
Study NCT02913417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
Study NCT01516242 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
Study NCT01362777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-patient rehabilitation
Description: Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~* 15' start warming up muscles~* 30' muscle strengthening exercise for arms and abdominal muscles~* 45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~* 15' stretching~* 15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe.
Study NCT01362777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational activities alone
Description: Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~* Physiological mechanisms of apneas/hypopneas~* Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~* Beneficials effects of CPAP and/or advanced mandibular orthosis~* Description of sleep stages and physiological roles of sleep~* Known effects of exercise on sleep and metabolism~* Importance of good nutritional status and sleep hygiene on quality of life~* How to apply theses lessons of rehabilitation in daily life
Study NCT02958267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMAC injection
Description: 60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
Study NCT02958267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: 60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
Study NCT02958267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gel-One® hyaluronate injection
Description: Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution \[10 mg/mL\], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
Study NCT01722110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Extended-Release Capsules USP 75 mg
Description: 75 mg tablet once a day
Study NCT01722110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin Extended Release Capsules USP 75 mg
Description: 75 mg tablet once a day
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
Study NCT00842114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R+CVP+IFN
Description: Immunochemotherapy
Study NCT01839487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
Study NCT02892084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
Study NCT02892084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill.
Study NCT01753232 — intervention group
Intervention type: DEVICE
Intervention: DALI-adsorber
Description: Recording of treatment data. No extra interventional treatment
Study NCT01468129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cell Saver
Study NCT03263286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandSOME
Description: Participants use the HandSOME orthosis daily for 8 weeks.
Study NCT04361942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml physiological saline solution.
Study NCT04361942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of 100 ml physiological saline solution containing no cells
Study NCT03990181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal matrix & NPPS
Description: Test meal consumed with the natural polyphenol supplement
Study NCT03990181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: meal matrix & CS
Description: Test meal consumed with the control supplement
Study NCT03990181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no-matrix & NPPS
Description: Test drink consumed with the natural polyphenol supplement
Study NCT03990181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no-matrix & CS
Description: Test drink consumed with the control supplement
Study NCT01767805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard incubator
Study NCT01767805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini incubator
Study NCT01767805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 5% oxygen
Study NCT01767805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 20% oxygen
Study NCT04290169 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IncobotulinumtoxinA
Description: IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
Study NCT04290169 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Video game
Description: The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo
Study NCT02568865 — intervention group
Intervention type: OTHER
Intervention: Physiological Sensors
Description: Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
Study NCT02568865 — intervention group
Intervention type: OTHER
Intervention: Sleep Monitoring Device
Description: The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
Study NCT02568865 — intervention group
Intervention type: OTHER
Intervention: Vocal Monitoring
Description: The participants will be provided with a phone app to leave audio diary recordings.
Study NCT02568865 — intervention group
Intervention type: OTHER
Intervention: Mobile Phone
Description: A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
Study NCT00775463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
Study NCT00775463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00589238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00589238 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Study NCT00589238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00589238 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin hydrochloride
Study NCT00589238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00589238 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Study NCT00589238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT03198182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT03198182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days
Study NCT03706313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15mL 0.25% bupivacaine
Description: Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
Study NCT03706313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block
Description: The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described.
Study NCT03706313 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Genicular nerve block
Description: The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described.
Study NCT03706313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
Study NCT02823535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iwin: Individual Well-Being Navigator
Description: Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
Study NCT03618121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback plus gaming (Nevermind)
Description: Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
Study NCT03618121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback only (The Pip)
Description: Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax \& Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
Study NCT03618121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation training
Description: Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
Study NCT03618121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming only
Description: Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices.
Study NCT01753232 — intervention group
Intervention type: DEVICE
Intervention: MONET-Lipoprotein filter
Description: Only treatment data recording. No extra interventional treatment
Study NCT04402372 — intervention group
Intervention type: DEVICE
Intervention: Novel bidirectional cannula (BiflowTM, LivaNova, Italy)
Description: We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
Study NCT02994446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline-Enhanced Radiofrequency Catheter and Ablation System
Description: Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Study NCT01011894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
Study NCT03276338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA
Description: To increase condom use and HIV testing
Study NCT03690687 — intervention group
Intervention type: PROCEDURE
Intervention: Primary anastomosis
Study NCT03690687 — intervention group
Intervention type: PROCEDURE
Intervention: Delayed anastomosis
Study NCT04183309 — intervention group
Intervention type: OTHER
Intervention: Measure the transpulmonary pressure in pediatric patients
Description: Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
Study NCT03690687 — intervention group
Intervention type: PROCEDURE
Intervention: Enterostomy
Study NCT01434212 — intervention group
Intervention type: DRUG
Intervention: Interferon Alfa-2b, Ribavirin
Description: Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.
Study NCT02345785 — intervention group
Intervention type: OTHER
Intervention: urologic surgery and caudal block
Study NCT02166125 — intervention group
Intervention type: PROCEDURE
Intervention: Endosuturing
Description: Endoscopic suturing
Study NCT03854175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: 25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle
Study NCT03854175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate 2 MG
Description: 2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium
Study NCT04450160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anhydrous Enol-Oxaloacetate (AEO)
Description: Oral supplementation with AEO along with the Standard of Care (Temozolomide)
Study NCT04450160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Temozolomide
Study NCT04450160 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Temozolomide
Study NCT03457038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Addition to the current care but during the normal follow-up visit :~* At the entrance to the service: search for bacterial 16S RNA in the blood~* Additional blood tests (4) at T6-12-18 and 36h~* At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~* 1 time per day: Assay of CRP and PCT from samples taken in common practice~* J30: Assessment of the vital status of the patient